Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan

Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan

Bibliographic Details
Main Authors:	Masako Matsutani, Yasutomo Imai, Yukako Inoue, Yuka Hosotani, Minori Kusakabe, Masaru Natsuaki, Kiyofumi Yamanishi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Series:	Journal of Cutaneous Immunology and Allergy
Online Access:	https://doi.org/10.1002/cia2.12099

Similar Items

Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022-04-01)

Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice
by: Marin Kunimoto, et al.
Published: (2022-04-01)

Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
by: Kanako Kita, et al.
Published: (2023-06-01)

Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report
by: Hideki Hayashi, et al.
Published: (2021-02-01)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023-06-01)

IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice
by: Yuka Hosotani, et al.
Published: (2023-04-01)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023-03-01)

Punctal stenosis associated with dupilumab therapy for atopic dermatitis
by: Debora H. Lee, et al.
Published: (2021-10-01)

Dupilumab for the treatment of adult atopic dermatitis in special populations
by: Cataldo Patruno, et al.
Published: (2022-10-01)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023-12-01)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022-05-01)

A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
by: Wang M, et al.
Published: (2024-03-01)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020-09-01)

Drug survival rate of dupilumab in Japanese patients with atopic dermatitis
by: Susumu Ichiyama, et al.
Published: (2021-10-01)

Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
by: Milena Tanczosova, et al.
Published: (2023-02-01)

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
by: Mikołaj Cichoń, et al.
Published: (2023-03-01)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis
by: Shinji Mitsuyama, et al.
Published: (2023-04-01)

Dupilumab for atopic dermatitis: what are patients learning on YouTube?
by: Deeti J. Pithadia, et al.
Published: (2022-01-01)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
by: Marco Dubini, et al.
Published: (2023-09-01)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
by: Mara Giavina-Bianchi, et al.
Published: (2021-05-01)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
by: Lotte S. Spekhorst, et al.
Published: (2023-01-01)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2022-10-01)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023-01-01)

Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
by: Marco Ferrari, et al.
Published: (2023-01-01)

Psoriasis‐like eruptions developed in an atopic dermatitis patient treated with dupilumab
by: Rai Fujimoto, et al.
Published: (2022-12-01)

Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience
by: Jowita Sroka-Tomaszewska, et al.
Published: (2024-01-01)

Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
by: Caterina Foti, et al.
Published: (2022-11-01)

Perception and Experience of Dupilumab in Atopic Dermatitis: A Real-Life Study
by: Antoine L, et al.
Published: (2023-09-01)

Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis,
by: Camilla Chello, et al.
Published: (2021-10-01)

Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients
by: Yan Guex-Crosier, et al.
Published: (2021-08-01)

Dupilumab for atopic dermatitis treatment: A single-center retrospective study
by: Gülbin Yaşar, et al.
Published: (2022-03-01)

Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab
by: Lishan Zhang, et al.
Published: (2022-10-01)

Effects of dupilumab on hair in patients with atopic dermatitis - a review of the literature
by: Aleksandra Marczak, et al.
Published: (2022-11-01)

Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab
by: Mingxia Wang, et al.
Published: (2022-06-01)

Successful Treatment of an Adult with Atopic Dermatitis and Lamellar Ichthyosis Using Dupilumab
by: Binkhonain FK, et al.
Published: (2022-06-01)

Dupilumab treatment of a case of asthma, chronic rhinosinusitis, and atopic dermatitis after initial benralizumab administration
by: Haruna Matsuda‐Hirose, et al.
Published: (2020-08-01)

Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab
by: George G. Mitroi, et al.
Published: (2022-10-01)